Recombinant Acinetobacter sp. Aspartate--tRNA ligase (AspRS), also known as aspS, is an enzyme crucial for protein synthesis in bacteria . Specifically, it catalyzes the attachment of aspartic acid to its corresponding transfer RNA (tRNA), a vital step in ensuring the correct amino acid sequence during translation . The "partial" designation typically indicates that the recombinant protein may not represent the full-length native enzyme but rather a fragment or domain of it, which is produced through recombinant DNA technology .
Aspartyl-tRNA synthetase (AspRS) belongs to the aminoacyl-tRNA synthetases (aaRSs), a family of enzymes essential for protein biosynthesis . These enzymes ensure the correct pairing of amino acids with their corresponding tRNAs, thereby maintaining the fidelity of the genetic code during protein synthesis .
Aminoacylation Reaction: AspRS catalyzes a two-step reaction. In the first step, it activates aspartic acid by linking it to ATP, forming aspartyl-adenylate. In the second step, it transfers the activated aspartic acid to the appropriate tRNA molecule, forming aspartyl-tRNA .
Non-discriminating AspRS: Unlike some bacteria, Acinetobacter may contain a non-discriminating form of AspRS, which initially attaches aspartic acid to tRNAAsn. This misacylated tRNA is then converted to asparagine by an amidotransferase enzyme .
AspRS is critical for bacterial growth and survival. It is involved in fundamental cellular processes, including:
Protein Synthesis: By ensuring the availability of correctly charged tRNA molecules, AspRS supports the continuous production of proteins necessary for bacterial metabolism, growth, and adaptation to environmental changes .
Low-Temperature Adaptation: In Acinetobacter harbinensis, genes related to amino acid metabolism are up-regulated at low temperatures, indicating the activation of amino acid metabolism to facilitate growth under such conditions .
AspRS has emerged as a promising target for developing new antibacterial agents . Inhibiting AspRS can disrupt protein synthesis, leading to bacterial growth inhibition and cell death. Several studies have explored this potential:
Inhibitor Identification: Researchers have identified chemical compounds that inhibit AspRS activity in Pseudomonas aeruginosa, demonstrating the feasibility of targeting this enzyme with small-molecule inhibitors .
Resistance Mechanisms: Studies involving Mycobacterium tuberculosis have shown that mutations in the aspS gene can lead to resistance against AspRS inhibitors, highlighting the importance of understanding resistance mechanisms in drug development .
Recombinant AspRS is produced using genetic engineering techniques, where the aspS gene is cloned and expressed in a host organism such as Escherichia coli . The recombinant enzyme can then be purified and used for various applications:
Structural Studies: Recombinant AspRS is used to determine the crystal structure of the enzyme, providing insights into its catalytic mechanism and potential drug-binding sites .
Enzyme Assays: Recombinant AspRS is used in biochemical assays to measure its activity and characterize its interactions with substrates and inhibitors .
Drug Screening: Recombinant AspRS is employed in high-throughput screening assays to identify novel inhibitors of the enzyme .
| Parameter | Value |
|---|---|
| KM (tRNAAsp/Asn) | 0.55 μM |
| kcat obs | 0.21 s-1 |
| kcat/KM | 0.38 μM-1 s-1 |
When recombinant bacterial L-asparaginase (ASNase) is expressed in human cells, it undergoes glycosylation, resulting in a larger molecular weight compared to its expression in Escherichia coli . This glycosylation can potentially reduce the antigenicity of the enzyme, which is significant for therapeutic applications in treating acute lymphoblastic leukemia (ALL) .
Aspartyl-tRNA synthetase displays relaxed tRNA specificity, as it can aspartylate not only its cognate tRNA(Asp) but also tRNA(Asn). The reaction proceeds in two steps: L-aspartate is first activated by ATP to form Asp-AMP, which is then transferred to the acceptor end of tRNA(Asp/Asn).
KEGG: aci:ACIAD0609
STRING: 62977.ACIAD0609
Aspartate-tRNA ligase (EC 6.1.1.12), also known as Aspartyl-tRNA synthetase (AspRS), is an essential enzyme responsible for charging tRNA^Asp with aspartate during protein synthesis. This enzyme catalyzes a critical step in translation by ensuring the correct amino acid is attached to its cognate tRNA, maintaining the fidelity of the genetic code. In Acinetobacter species, AspRS is encoded by the aspS gene and functions within the complex machinery of protein synthesis .
AspRS enzymes are classified into two main functional categories: discriminating and non-discriminating forms. Discriminating AspRS specifically charges tRNA^Asp with aspartate but cannot acylate tRNA^Asn. In contrast, non-discriminating AspRS can misacylate tRNA^Asn with aspartate, creating Asp-tRNA^Asn as an intermediate. This misacylated tRNA is later corrected by amidotransferases to form Asn-tRNA^Asn. While it was previously thought that bacterial AspRS enzymes were exclusively discriminating and archaeal ones non-discriminating, research has shown that both forms exist in archaea, highlighting the evolutionary complexity of these enzymes .
Acinetobacter AspRS exhibits a multi-domain architecture typical of class II aminoacyl-tRNA synthetases:
| Domain | Location | Primary Function | Secondary Functions |
|---|---|---|---|
| N-terminal | N-terminus | tRNA anticodon recognition | Species-specific interactions |
| Catalytic core | Central region | Aspartate activation and transfer | ATP binding, active site formation |
| Insertion domain | Within catalytic core | Substrate specificity | Structural stability |
| C-terminal | C-terminus | tRNA acceptor stem binding | Positioning of tRNA for aminoacylation |
Based on product specifications, researchers should follow these guidelines for optimal handling:
| Parameter | Recommendation | Notes |
|---|---|---|
| Reconstitution medium | Deionized sterile water | Concentration: 0.1-1.0 mg/mL |
| Stabilizing agent | Glycerol (5-50%) | Default: 50% final concentration |
| Storage temperature | -20°C/-80°C | Liquid form: ~6 months shelf life Lyophilized form: ~12 months shelf life |
| Working storage | 4°C | Up to one week |
| Handling precautions | Brief centrifugation before opening | Avoid repeated freeze-thaw cycles |
Proper reconstitution and storage are essential for maintaining enzymatic activity and ensuring experimental reproducibility .
Several complementary approaches allow researchers to evaluate different aspects of AspRS function:
ATP-PPi exchange assay: Measures the first step of aminoacylation (amino acid activation) independent of tRNA charging.
tRNA aminoacylation assay: Quantifies the rate of aspartate attachment to tRNA^Asp using radioisotope-labeled aspartate or ATP.
Thin-layer chromatography (TLC): Can be used to separate and visualize charged from uncharged tRNAs, as demonstrated with tRNA modifications in Acinetobacter studies .
LC-MS analysis: Provides precise quantification of aminoacylated tRNAs and can detect modifications, similar to techniques used to analyze m^7G modifications in Acinetobacter tRNAs .
Gel mobility shift assays: Assess the binding affinity between AspRS and its tRNA substrates through electrophoretic mobility differences.
Based on methodologies applied to related tRNA-modifying enzymes in Acinetobacter, researchers can follow this procedure:
Design primers flanking the aspS gene or target region with appropriate overlaps for subsequent cloning steps.
Use overlap extension PCR to fuse fragments with an antibiotic resistance cassette (e.g., apramycin resistance).
Electroporate the purified linear DNA product into Acinetobacter strains containing a recombinase-expressing plasmid (such as pAT04 with IPTG-inducible RecAB).
Select transformants using appropriate antibiotics and confirm gene replacement through whole-genome sequencing.
For marker removal, introduce a plasmid encoding FLP recombinase (such as PAT03) to excise the antibiotic cassette if FRT sites were included.
For complementation studies, use mini-Tn7 systems (such as pUCT18T-miniTn7-Zeo) to reintroduce the wild-type gene at a neutral site in the chromosome .
While AspRS itself has not been directly studied in Acinetobacter stress responses, research on other tRNA-modifying enzymes provides valuable insights into potential parallels. The tRNA methyltransferase TrmB in Acinetobacter baumannii has been shown to be critical for responses to oxidative stress, low pH, and iron deprivation - all conditions encountered during infection. Loss of TrmB dramatically attenuates virulence in murine pneumonia models .
By extension, as a key enzyme in translation, AspRS likely plays a role in:
Maintaining translational fidelity under stress conditions
Supporting adaptation to hostile host environments
Enabling appropriate expression of virulence factors
Contributing to antibiotic tolerance mechanisms
The essential nature of AspRS makes it a potential target for antimicrobial development, particularly given the rise of multidrug-resistant Acinetobacter strains .
Recombinant partial AspRS proteins offer several advantages for drug discovery efforts:
They provide accessible molecular targets for high-throughput screening of potential inhibitors.
The partial protein may contain key catalytic domains while being easier to express and manipulate than the full-length enzyme.
Structural studies of partial AspRS can reveal binding pockets and interaction sites for rational drug design.
Comparison between bacterial AspRS and human homologs can identify bacterial-specific features for selective targeting.
Partial AspRS constructs can serve as tools for validating hit compounds before progressing to whole-cell assays.
Recent efforts to develop inhibitors against another tRNA methyltransferase, TrmD, highlight the therapeutic potential of targeting tRNA-modifying enzymes to combat multidrug-resistant A. baumannii .
The genomic neighborhood of aspS provides important insights into its evolutionary and functional relationships:
The presence or absence of genes encoding asparaginyl-tRNA synthetase (AsnRS) and Asp-tRNA^Asn amidotransferase in the genome correlates with whether AspRS is discriminating or non-discriminating.
Species with non-discriminating AspRS typically lack AsnRS but possess amidotransferase genes, supporting the indirect pathway for Asn-tRNA^Asn formation.
Conversely, species with discriminating AspRS generally possess AsnRS but lack amidotransferase genes, utilizing the direct aminoacylation pathway .
This genomic context analysis helps researchers predict the functional characteristics of AspRS in different Acinetobacter strains and understand the evolutionary pressures shaping aminoacyl-tRNA synthetase systems.
To explore the relationship between AspRS and stress adaptation, researchers can implement these sophisticated approaches:
Conditional depletion systems: Utilize inducible promoters or degradation tags to modulate AspRS levels and assess the impact on stress response pathways.
Ribosome profiling: Compare translational profiles between wild-type and AspRS-depleted cells under various stress conditions to identify differentially translated mRNAs.
Proteomics analysis: Similar to studies with TrmB mutants, examine how altered AspRS activity affects protein expression during stress responses, particularly focusing on stress-response regulons and virulence factors .
Post-transcriptional regulation analysis: Investigate whether AspRS is subject to post-transcriptional control during stress, similar to the regulation observed for acinetobactin cluster proteins in response to oxidative stress .
In vivo infection models: Assess how AspRS mutations or inhibition affects bacterial survival during host infection, immune clearance, and disease progression.
Developing selective inhibitors requires sophisticated screening and validation strategies:
Structure-based virtual screening: Use computational methods to identify compounds that bind to unique pockets in Acinetobacter AspRS.
Fragment-based drug discovery: Screen small molecular fragments for binding to AspRS and optimize hits through medicinal chemistry.
High-throughput biochemical assays: Develop miniaturized assays to screen compound libraries for inhibition of AspRS activity.
Selectivity profiling: Test promising compounds against human DARS (cytosolic) and DARS2 (mitochondrial) aspartyl-tRNA synthetases to ensure bacterial selectivity.
Resistance development studies: Assess the potential for resistance development by selecting for mutations that confer resistance to AspRS inhibitors.
Combinatorial approaches: Explore synergistic inhibition of multiple tRNA-processing enzymes, such as combining AspRS inhibitors with those targeting TrmB or other tRNA methyltransferases .
Evolutionary analysis of AspRS can provide insights into bacterial adaptation processes:
Sequence conservation analysis: Comparative genomics across Acinetobacter species can reveal conserved regions essential for function versus variable regions that may contribute to species-specific adaptations.
Positive selection detection: Statistical methods can identify amino acid positions under positive selection pressure, potentially indicating adaptation to host environments.
Horizontal gene transfer assessment: Analysis of codon usage, GC content, and phylogenetic incongruence can detect horizontal acquisition of aspS genes or domains.
Host-pathogen co-evolution: Comparison of AspRS sequences from isolates adapted to different hosts may reveal host-specific adaptations.
Mutational pathway reconstruction: Experimental evolution studies combined with structural analysis can elucidate how mutations in AspRS affect enzyme function and bacterial fitness.
The high sequence identity (up to 60%) observed between discriminating and non-discriminating archaeal AspRS enzymes suggests that relatively few mutations may be required to alter tRNA discrimination properties, highlighting the adaptability of these essential enzymes .
Researchers frequently encounter several technical challenges:
| Challenge | Potential Causes | Recommended Solutions |
|---|---|---|
| Low protein yield | Poor expression, inclusion body formation | Optimize induction conditions, expression temperature, consider fusion tags |
| Loss of activity | Improper folding, cofactor loss | Include stabilizing agents, maintain reducing environment |
| Batch variability | Expression conditions, purification differences | Standardize protocols, implement quality control testing |
| Storage instability | Aggregation, oxidation, proteolysis | Add stabilizers (glycerol), aliquot to avoid freeze-thaw cycles |
| Contamination | Host cell nucleic acids, proteases | Include DNase/RNase treatment, add protease inhibitors |
Implementing rigorous quality control procedures and standardized handling protocols can minimize these challenges and ensure consistent experimental results.
To ensure accurate characterization of enzyme specificity:
Substrate panel testing: Assess activity with various amino acids and tRNAs to confirm aspartate and tRNA^Asp specificity.
Mischarging detection: Test whether the AspRS can charge tRNA^Asn with aspartate to determine if it is discriminating or non-discriminating.
Amidotransferase coupling assay: If available, use Asp-tRNA^Asn amidotransferase to verify formation of Asp-tRNA^Asn, as demonstrated in studies with M. thermautotrophicus AspRS .
Competition assays: Examine the ability of non-cognate amino acids or tRNAs to inhibit the canonical reaction.
Kinetic parameter determination: Compare kinetic constants (K_m, k_cat) for cognate versus non-cognate substrates to quantify specificity differences.
These approaches provide a comprehensive assessment of AspRS specificity, which is essential for understanding its biological role and potential as a drug target.